AFC
VRTX icon

Ares Financial Consulting’s Vertex Pharmaceuticals VRTX Stock Holding History

Ares Financial Consulting’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
245
+5
+2% +$2.22K 0.09% 127
2026
Q1 		$107K Buy
240
+167
+229% +$77.9K 0.08% 123
2025
Q4 		$33.1K Buy
+73
New +$31.5K 0.03% 205

Other funds holding VRTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Ares Financial Consulting's VRTX Position: Q2 2026 in Review

Ares Financial Consulting increased its Vertex Pharmaceuticals (VRTX) stake by 2.1% in Q2 2026, buying an estimated $2.22K and bringing the position to 245 shares worth $122K. The position accounts for 0.09% of the portfolio, ranked #127.

Ares Financial Consulting first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 884 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Ares Financial Consulting held 245 shares of Vertex Pharmaceuticals worth $122K as of Q2 2026.
  • Ares Financial Consulting bought 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
  • Vertex Pharmaceuticals made up 0.09% of Ares Financial Consulting's portfolio in Q2 2026, its #127 holding.
  • Ares Financial Consulting first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 884 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.